doi: 10.3390/pharmaceutics15020699 279 UndeJSShuklaR
Efficacy Results of a SURPASS open-label, phase III trial, published in 2021, demonstrated tirzepatides superior glycaemic efficacy and weight reduction compared with existing GLP-1 receptor agonists, including semaglutide 6
G Ital Dermatol Venereol 154(6):609623
Ipamorelin Within the Research Peptide Catalogue Ipamorelin occupies the ghrelin receptor agonist / GHRP position within our GH-axis research toolkit mechanistically complementary to, and synergistic with, the GHRH-axis compounds CJC-1295 No DAC and tesamorelin, and distinct from the direct GH replacement approach of rhGH
Yaksh et al
analyzed 560 metabolites in serum metabolomics of patients with cirrhosis at different stages and found that IPA was the most significant indicator of decompensated metabolic biomarker reduction, suggesting that IPA can help accurately predict the stage of cirrhosis (Li et al., 2024)